<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/285a–11" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/285a–11/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/285a–11/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_285a_11"><akn:num>285a–11</akn:num><akn:heading>Pediatric cancer research, awareness, and survivorship</akn:heading><akn:content><akn:p>§ 285a–11. Pediatric cancer research, awareness, and survivorship(a) Children’s cancer biorepositories(1) AwardThe Secretary, acting through the Director of NIH, may make awards to an entity or entities described in paragraph (4) to build upon existing research efforts to collect biospecimens and clinical and demographic information of children, adolescents, and young adults with selected cancer subtypes (and their recurrences) for which current treatments are least effective, in order to achieve a better understanding of the causes of such cancer subtypes (and their recurrences), and the effects and outcomes of treatments for such cancers.


(2) Use of fundsAmounts received under an award under paragraph (1) may be used to carry out the following:(A) Collect and store high-quality, donated biospecimens and associated clinical and demographic information on children, adolescents, and young adults diagnosed with cancer in the United States, focusing on children, adolescents, and young adults with cancer enrolled in clinical trials for whom current treatments are least effective. Activities under this subparagraph may include storage of biospecimens and associated clinical and demographic data at existing biorepositories supported by the National Cancer Institute, such as collected samples of both solid tumor cancer and paired samples.

(B) Maintain an interoperable, secure, and searchable database on stored biospecimens and associated clinical and demographic data from children, adolescents, and young adults with cancer for the purposes of research by scientists and qualified health care professionals.

(C) Establish and implement procedures for evaluating applications for access to such biospecimens and clinical and demographic data from researchers and other qualified health care professionals.

(D) Provide access to biospecimens and clinical and demographic data from children, adolescents, and young adults with cancer to researchers and qualified health care profe</akn:p></akn:content><akn:subsection eId="subsec_285a_11_a"><akn:num>(a)</akn:num><akn:heading>Children’s cancer biorepositories</akn:heading><akn:content><akn:p>(a) Children’s cancer biorepositories</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_285a_11_b"><akn:num>(b)</akn:num><akn:heading>Improving care for pediatric cancer survivors</akn:heading><akn:content><akn:p>(b) Improving care for pediatric cancer survivors</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_285a_11_c"><akn:num>(c)</akn:num><akn:heading>Rule of construction</akn:heading><akn:content><akn:p>(c) Rule of construction Nothing in this section shall be construed as being inconsistent with the goals and purposes of the Minority Health and Health Disparities Research and Education Act of 2000.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_285a_11_d"><akn:num>(d)</akn:num><akn:heading>Authorization of appropriations</akn:heading><akn:content><akn:p>(d) Authorization of appropriations For purposes of carrying out this section and section 280e–3a of this title, there are authorized to be appropriated $30,000,000 for each of fiscal years 2024 through 2028. Funds appropriated under this subsection shall remain available until expended.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>